Key Drivers
- Robust Cash Flow
- Net Cash Position
- Premium Valuation
AIAI Summary
ALGN is a financially resilient recovery-and-execution story—not a proven premium-growth compounder—so investors should wait for tangible evidence of accelerating Invisalign case growth, stable pricing, and operating-margin recovery before underwriting its valuation; downside remains elevated if consumer weakness and China pricing pressure persist.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Robust Cash Flow
- •Net Cash Position
- •Premium Valuation
ALGN has strong profitability, cash flow, and net cash, but its premium valuation and sizable receivables/deferred revenue warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Weak momentum
ALGN fell about 9% over the last month, with support at $147–$148 and a rebound above $153–$154 needed to ease the bearish short-term trend.
Steady 9% decline over the last month
Sentiment & News
Key News Insights:
- •Growth Runway
- •Earnings Pressure
- •Institutional Buying
Align faces near-term pressure from weak spending, FX risks, and post-earnings weakness, but Invisalign/iTero growth, institutional buying, and elevated options activity support longer-term upside.
Near-term volatility may persist, but sustained adoption trends could improve sentiment over time
Similar Companies in Healthcare
Other companies in the same sector with AI ratings